- $60.77m
- -$32.07m
- $73.48m
- 39
- 63
- 29
- 40
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.53 | ||
| Price to Tang. Book | 0.53 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.85 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -60.4% | ||
| Return on Equity | -58.92% | ||
| Operating Margin | -133.51% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 65.21 | 78.65 | 85.49 | 65.05 | 73.48 | 76.97 | 84.79 | 14.23% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Personalis, Inc. is engaged in developing and marketing advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other next generation cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies.
Directors
- Jonathan Macquitty NEC (68)
- John West PRE (64)
- Aaron Tachibana CFO (60)
- Susan Moriconi CHO
- Richard Chen CSO (50)
- A. Blaine Bowman IND (74)
- Alan Colowick IND (58)
- Karin Eastham IND (71)
- Kenneth Ludlum IND (67)
- Woodrow Myers IND (67)
- Paul Ricci IND (67)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- February 21st, 2011
- Public Since
- June 20th, 2019
- No. of Shareholders
- 60
- No. of Employees
- 223
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 51,938,839
- Address
- 6600 Dumbarton Circle, FREMONT, 94555
- Web
- https://www.personalis.com/
- Phone
- +1 6507521300
- Auditors
- BDO USA, P.C.
Upcoming Events for PSNL
Q2 2024 Personalis Inc Earnings Release
Q3 2024 Personalis Inc Earnings Release
Similar to PSNL
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Personalis share price?
As of Today at 22:38 UTC, shares in Personalis are trading at $1.22. This share price information is delayed by 15 minutes.
How has the Personalis share price performed this year?
Shares in Personalis last closed at $1.22 and the price had moved by -40.49% over the past 365 days. In terms of relative price strength the Personalis share price has underperformed the S&P500 Index by -52.64% over the past year.
What are the analyst and broker recommendations for Personalis?
The overall consensus recommendation for Personalis is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Personalis dividend yield?
Personalis does not currently pay a dividend.
Does Personalis pay a dividend?
Personalis does not currently pay a dividend.
When does Personalis next pay dividends?
Personalis does not currently pay a dividend.
How do I buy Personalis shares?
To buy shares in Personalis you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Personalis?
As of the previous close price of $1.22, shares in Personalis had a market capitalisation of $63.37m.
Where are Personalis shares listed?
Here are the trading details for Personalis:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: PSNL
What kind of share is Personalis?
Based on an overall assessment of its quality, value and momentum Personalis is currently classified as a Value Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Personalis share price forecast for 2024?
The analyst consensus target price for shares in Personalis is $4.60. That is 277.05% above the last closing price of $1.22.
Analysts covering Personalis currently have a consensus Earnings Per Share (EPS) forecast of -$1.41 for the next financial year.
What is the trend in the Personalis share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Personalis. Over the past six months, its share price has underperformed the S&P500 Index by -27.24%.
As of the last closing price of $1.22, shares in Personalis were trading -13.05% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Personalis PE Ratio?
The Personalis PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.22.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Personalis?
Personalis' management team is headed by:
- Jonathan Macquitty - NEC
- John West - PRE
- Aaron Tachibana - CFO
- Susan Moriconi - CHO
- Richard Chen - CSO
- A. Blaine Bowman - IND
- Alan Colowick - IND
- Karin Eastham - IND
- Kenneth Ludlum - IND
- Woodrow Myers - IND
- Paul Ricci - IND